Regulatory flexibility can make continuous improvement possible.
Bruce Meiklejohn
Advertisement
Bruce Meiklejohn is a principal fellow, regulatory COE-biotech at Eli Lilly and Company
Articles by Bruce Meiklejohn
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3January 1st 2010
Quality by Design for Biotechnology Products—Part 2December 1st 2009
Quality by Design for Biotechnology Products—Part 1November 1st 2009
Advertisement
Advertisement